H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells

Laura Pandolfi, Michela Bellini, Renzo Vanna, Carlo Morasso, Andrea Zago, Sofia Carcano, Svetlana Avvakumova, Jessica Armida Bertolini, Maria Antonietta Rizzuto, Miriam Colombo, Davide Prosperi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Triple negative breast cancer (TNBC) is a highly aggressive, invasive, and metastatic tumor. Although it is reported to be sensitive to cytotoxic chemotherapeutics, frequent relapse and chemoresistance often result in treatment failure. In this study, we developed a biomimetic nanodrug consisting of a self-assembling variant (HFn) of human apoferritin loaded with curcumin. HFn nanocage improved the solubility, chemical stability, and bioavailability of curcumin, allowing us to reliably carry out several experiments in the attempt to establish the potential of this molecule as a therapeutic agent and elucidate the mechanism of action in TNBC. HFn biopolymer was designed to bind selectively to the TfR1 receptor overexpressed in TNBC cells. HFn-curcumin (CFn) proved to be more effective in viability assays compared to the drug alone using MDA-MB-468 and MDA-MB-231 cell lines, representative of basal and claudin-low TNBC subtypes, respectively. Cellular uptake of CFn was demonstrated by flow cytometry and label-free confocal Raman imaging. CFn could act as a chemosensitizer enhancing the cytotoxic effect of doxorubicin by interfering with the activity of multidrug resistance transporters. In addition, CFn exhibited different cell cycle effects on these two TNBC cell lines, blocking MDA-MB-231 in G0/G1 phase, whereas MDA-MB-468 accumulated in G2/M phase. CFn was able to inhibit the Akt phosphorylation, suggesting that the effect on the proliferation and cell cycle involved the alteration of PI3K/Akt pathway.

Original languageEnglish
Pages (from-to)3318-3330
Number of pages13
JournalBiomacromolecules
Volume18
Issue number10
DOIs
Publication statusPublished - Oct 9 2017

Fingerprint

Apoferritins
Curcumin
Cells
Phosphorylation
Biopolymers
Flow cytometry
Chemical stability
Biomimetics
Phosphatidylinositol 3-Kinases
Doxorubicin
Labels
Tumors
Assays
Solubility
Imaging techniques
Molecules
Pharmaceutical Preparations
Experiments

ASJC Scopus subject areas

  • Bioengineering
  • Biomaterials
  • Polymers and Plastics
  • Materials Chemistry

Cite this

H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells. / Pandolfi, Laura; Bellini, Michela; Vanna, Renzo; Morasso, Carlo; Zago, Andrea; Carcano, Sofia; Avvakumova, Svetlana; Bertolini, Jessica Armida; Rizzuto, Maria Antonietta; Colombo, Miriam; Prosperi, Davide.

In: Biomacromolecules, Vol. 18, No. 10, 09.10.2017, p. 3318-3330.

Research output: Contribution to journalArticle

Pandolfi, L, Bellini, M, Vanna, R, Morasso, C, Zago, A, Carcano, S, Avvakumova, S, Bertolini, JA, Rizzuto, MA, Colombo, M & Prosperi, D 2017, 'H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells', Biomacromolecules, vol. 18, no. 10, pp. 3318-3330. https://doi.org/10.1021/acs.biomac.7b00974
Pandolfi, Laura ; Bellini, Michela ; Vanna, Renzo ; Morasso, Carlo ; Zago, Andrea ; Carcano, Sofia ; Avvakumova, Svetlana ; Bertolini, Jessica Armida ; Rizzuto, Maria Antonietta ; Colombo, Miriam ; Prosperi, Davide. / H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells. In: Biomacromolecules. 2017 ; Vol. 18, No. 10. pp. 3318-3330.
@article{c2fe2e3a99a7480ba7dcf6f0f0fe7893,
title = "H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells",
abstract = "Triple negative breast cancer (TNBC) is a highly aggressive, invasive, and metastatic tumor. Although it is reported to be sensitive to cytotoxic chemotherapeutics, frequent relapse and chemoresistance often result in treatment failure. In this study, we developed a biomimetic nanodrug consisting of a self-assembling variant (HFn) of human apoferritin loaded with curcumin. HFn nanocage improved the solubility, chemical stability, and bioavailability of curcumin, allowing us to reliably carry out several experiments in the attempt to establish the potential of this molecule as a therapeutic agent and elucidate the mechanism of action in TNBC. HFn biopolymer was designed to bind selectively to the TfR1 receptor overexpressed in TNBC cells. HFn-curcumin (CFn) proved to be more effective in viability assays compared to the drug alone using MDA-MB-468 and MDA-MB-231 cell lines, representative of basal and claudin-low TNBC subtypes, respectively. Cellular uptake of CFn was demonstrated by flow cytometry and label-free confocal Raman imaging. CFn could act as a chemosensitizer enhancing the cytotoxic effect of doxorubicin by interfering with the activity of multidrug resistance transporters. In addition, CFn exhibited different cell cycle effects on these two TNBC cell lines, blocking MDA-MB-231 in G0/G1 phase, whereas MDA-MB-468 accumulated in G2/M phase. CFn was able to inhibit the Akt phosphorylation, suggesting that the effect on the proliferation and cell cycle involved the alteration of PI3K/Akt pathway.",
author = "Laura Pandolfi and Michela Bellini and Renzo Vanna and Carlo Morasso and Andrea Zago and Sofia Carcano and Svetlana Avvakumova and Bertolini, {Jessica Armida} and Rizzuto, {Maria Antonietta} and Miriam Colombo and Davide Prosperi",
year = "2017",
month = "10",
day = "9",
doi = "10.1021/acs.biomac.7b00974",
language = "English",
volume = "18",
pages = "3318--3330",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - H-Ferritin Enriches the Curcumin Uptake and Improves the Therapeutic Efficacy in Triple Negative Breast Cancer Cells

AU - Pandolfi, Laura

AU - Bellini, Michela

AU - Vanna, Renzo

AU - Morasso, Carlo

AU - Zago, Andrea

AU - Carcano, Sofia

AU - Avvakumova, Svetlana

AU - Bertolini, Jessica Armida

AU - Rizzuto, Maria Antonietta

AU - Colombo, Miriam

AU - Prosperi, Davide

PY - 2017/10/9

Y1 - 2017/10/9

N2 - Triple negative breast cancer (TNBC) is a highly aggressive, invasive, and metastatic tumor. Although it is reported to be sensitive to cytotoxic chemotherapeutics, frequent relapse and chemoresistance often result in treatment failure. In this study, we developed a biomimetic nanodrug consisting of a self-assembling variant (HFn) of human apoferritin loaded with curcumin. HFn nanocage improved the solubility, chemical stability, and bioavailability of curcumin, allowing us to reliably carry out several experiments in the attempt to establish the potential of this molecule as a therapeutic agent and elucidate the mechanism of action in TNBC. HFn biopolymer was designed to bind selectively to the TfR1 receptor overexpressed in TNBC cells. HFn-curcumin (CFn) proved to be more effective in viability assays compared to the drug alone using MDA-MB-468 and MDA-MB-231 cell lines, representative of basal and claudin-low TNBC subtypes, respectively. Cellular uptake of CFn was demonstrated by flow cytometry and label-free confocal Raman imaging. CFn could act as a chemosensitizer enhancing the cytotoxic effect of doxorubicin by interfering with the activity of multidrug resistance transporters. In addition, CFn exhibited different cell cycle effects on these two TNBC cell lines, blocking MDA-MB-231 in G0/G1 phase, whereas MDA-MB-468 accumulated in G2/M phase. CFn was able to inhibit the Akt phosphorylation, suggesting that the effect on the proliferation and cell cycle involved the alteration of PI3K/Akt pathway.

AB - Triple negative breast cancer (TNBC) is a highly aggressive, invasive, and metastatic tumor. Although it is reported to be sensitive to cytotoxic chemotherapeutics, frequent relapse and chemoresistance often result in treatment failure. In this study, we developed a biomimetic nanodrug consisting of a self-assembling variant (HFn) of human apoferritin loaded with curcumin. HFn nanocage improved the solubility, chemical stability, and bioavailability of curcumin, allowing us to reliably carry out several experiments in the attempt to establish the potential of this molecule as a therapeutic agent and elucidate the mechanism of action in TNBC. HFn biopolymer was designed to bind selectively to the TfR1 receptor overexpressed in TNBC cells. HFn-curcumin (CFn) proved to be more effective in viability assays compared to the drug alone using MDA-MB-468 and MDA-MB-231 cell lines, representative of basal and claudin-low TNBC subtypes, respectively. Cellular uptake of CFn was demonstrated by flow cytometry and label-free confocal Raman imaging. CFn could act as a chemosensitizer enhancing the cytotoxic effect of doxorubicin by interfering with the activity of multidrug resistance transporters. In addition, CFn exhibited different cell cycle effects on these two TNBC cell lines, blocking MDA-MB-231 in G0/G1 phase, whereas MDA-MB-468 accumulated in G2/M phase. CFn was able to inhibit the Akt phosphorylation, suggesting that the effect on the proliferation and cell cycle involved the alteration of PI3K/Akt pathway.

UR - http://www.scopus.com/inward/record.url?scp=85031280368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031280368&partnerID=8YFLogxK

U2 - 10.1021/acs.biomac.7b00974

DO - 10.1021/acs.biomac.7b00974

M3 - Article

AN - SCOPUS:85031280368

VL - 18

SP - 3318

EP - 3330

JO - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 10

ER -